BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 36347013)

  • 21. The Impact of JAK2 V617F, CALR, and MPL Mutations as Molecular Diagnostic Markers of Myeloproliferative Neoplasms in Kurdish Patients. A Single-center Experience.
    Basim Najm M; Jalal SD; Getta HA
    Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):202-209. PubMed ID: 36800830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Tefferi A
    Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental Modeling of Myeloproliferative Neoplasms.
    Lanikova L; Babosova O; Prchal JT
    Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31618985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
    Lin Y; Liu E; Sun Q; Ma J; Li Q; Cao Z; Wang J; Jia Y; Zhang H; Song Z; Ai X; Shi L; Feng X; Li C; Wang J; Ru K
    Am J Clin Pathol; 2015 Jul; 144(1):165-71. PubMed ID: 26071474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
    Alshemmari SH; Rajan R; Ameen R; Almazyad M
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):483-488. PubMed ID: 33858806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
    Tefferi A; Guglielmelli P; Larson DR; Finke C; Wassie EA; Pieri L; Gangat N; Fjerza R; Belachew AA; Lasho TL; Ketterling RP; Hanson CA; Rambaldi A; Finazzi G; Thiele J; Barbui T; Pardanani A; Vannucchi AM
    Blood; 2014 Oct; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of
    Abbou N; Piazzola P; Gabert J; Ernest V; Arcani R; Couderc AL; Tichadou A; Roche P; Farnault L; Colle J; Ouafik L; Morange P; Costello R; Venton G
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611899
    [No Abstract]   [Full Text] [Related]  

  • 28. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
    Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
    Misawa K; Yasuda H; Araki M; Ochiai T; Morishita S; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
    Int J Hematol; 2018 Jun; 107(6):673-680. PubMed ID: 29464483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).
    Zulkeflee RH; Zulkafli Z; Johan MF; Husin A; Islam MA; Hassan R
    Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34300032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical application of gene mutation information in myeloproliferative neoplasms].
    Takenaka K
    Rinsho Ketsueki; 2019; 60(6):610-618. PubMed ID: 31281152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
    Milosevic Feenstra JD; Nivarthi H; Gisslinger H; Leroy E; Rumi E; Chachoua I; Bagienski K; Kubesova B; Pietra D; Gisslinger B; Milanesi C; Jäger R; Chen D; Berg T; Schalling M; Schuster M; Bock C; Constantinescu SN; Cazzola M; Kralovics R
    Blood; 2016 Jan; 127(3):325-32. PubMed ID: 26423830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Not Available].
    Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low
    Makarik TV; Abdullaev AO; Nikulina EE; Treglazova SA; Stepanova EE; Subortseva IN; Kovrigina AM; Melikyan AL; Kulikov SM; Sudarikov AB
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33921387
    [No Abstract]   [Full Text] [Related]  

  • 36. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloproliferative neoplasms: Current molecular biology and genetics.
    Saeidi K
    Crit Rev Oncol Hematol; 2016 Feb; 98():375-89. PubMed ID: 26697989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in
    Pan Y; Wang X; Wen S; Liu X; Yang L; Luo J
    Hematology; 2022 Dec; 27(1):902-908. PubMed ID: 36000955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
    Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
    J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.